Company Encyclopedia
View More
name
Traws Pharma
TRAW.US
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University.
4.359 T
TRAW.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking100/180
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.48%B
    • Profit Margin-613.92%E
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY1184.51%A
    • Net Profit YoY88.32%A
    • Total Assets YoY-16.40%E
    • Net Assets YoY35.46%A
  • Cash ScoreB
    • Cash Flow Margin-56.94%D
    • OCF YoY1184.51%A
  • Operating ScoreD
    • Turnover0.17D
  • Debt ScoreC
    • Gearing Ratio47.11%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Traws Pharma | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TRAW
    +39.55%
    LB filings·
    US
    TRAW
    +39.55%

    Traws Pharma Reports Q3 2025 Financial Results

    Traws Pharma announced Q3 2025 financial results, highlighting cost reductions, intellectual property acquisitions, and a strategic shift towards antiviral programs. The company is advancing Phase 2 studies for COVID-19 and flu therapies. Despite a decrease in net loss, Spark rates TRAW stock as Underperform due to financial challenges. Recent positive trial data and new financing offer hope for future improvements. Traws Pharma focuses on developing therapies for respiratory viral diseases, targeting significant market opportunities.

    Tip Ranks·
    US
    TRAW
    +39.55%
    Tip Ranks·
    US
    TRAW
    +39.55%

    Traws Pharma | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TRAW
    +39.55%
    LB filings·
    US
    TRAW
    +39.55%

    Traws Pharma posts $4.0 million net loss on zero revenue for Q3 2025

    Traws Pharma Inc. reported a net loss of $4.0 million for Q3 2025, compared to a net loss of $8.5 million in Q3 2024. The company had zero revenue for the quarter, down from $57,000 in the prior year. Research and development expenses were $2.3 million, and general and administrative expenses were $1.7 million. Traws Pharma acquired intellectual property from Viriom, Inc. for $2.6 million and continued Phase 2 studies for ratutrelvir.

    Reuters·
    US
    TRAW
    +39.55%
    Reuters·
    US
    TRAW
    +39.55%

    Traws Pharma Extends CMC Services Contract With ChemDiv for Ratutrelvir Clinical Development

    Traws Pharma Inc. has extended its contract with ChemDiv for CMC services to support the clinical development of ratutrelvir, an oral antiviral for COVID-19 in Phase 2 trials. The agreement includes CMC process research, medicinal chemistry support, and clinical pharmacology consulting. Additionally, Expert Systems has also extended its contract with Traws Pharma for predictive safety pharmacology services using AI to aid further clinical development of ratutrelvir.

    Reuters·
    US
    TRAW
    +39.55%
    Reuters·
    US
    TRAW
    +39.55%